Ondansetron Orally Disintegrating Tablets
ID: SPE2D2-25-R-0018Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
    Description

    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.

    Point(s) of Contact
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Presolicitation
    Similar Opportunities
    Ondansetron 4MG and 8MG
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ondansetron. This contract will establish a national supply source to provide Ondansetron HCL 4 and 8MG Tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The projected solicitation date is March of 2023.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Metaxalone Tablets
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Metaxalone Tablets, specifically 800 MG tablets available in 100-count and 500-count bottles. This procurement aims to secure a reliable supply of this pharmaceutical product, which is essential for various medical applications within military healthcare. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, by 3:00 PM EST, and are required to adhere to specific contract terms, including a subcontracting plan for large businesses and compliance with various federal regulations. For further inquiries, potential offerors can contact Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil.
    Trazodone - Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Trazodone tablets in various dosages and bottle counts. This procurement aims to secure a substantial quantity of pharmaceutical supplies essential for military and healthcare operations. Offerors are required to submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 12, 2025, at 3:00 PM EST, with no alternative submission methods accepted. Interested parties can reach out to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries regarding the solicitation.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Metformin HCL
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Ibuprofen 400MG/600MG/800MG Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ibuprofen 400MG/600MG/800MG Tablets. The contract will establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is March of 2023.
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to establish Blanket Purchase Agreements (BPAs) and an Additional Discount Program (ADP) as part of its Uniform Formulary for the Military Health System. This procurement aims to secure effective and cost-efficient pharmaceutical agents, including newly approved drugs for various therapeutic classes, which will be evaluated by the Pharmacy and Therapeutics (P&T) Committee for inclusion in the formulary. The selected agents will play a crucial role in providing essential medications to military personnel and their families, ensuring access to high-quality healthcare. Interested manufacturers must submit their quotes by January 5, 2026, with a pre-quotation teleconference scheduled for December 17, 2025; for further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Julia Trang at julia.n.trang.civ@health.mil.
    DLA MedSurg Prime Vendor Gen VI
    Dept Of Defense
    The Defense Logistics Agency (DLA) is seeking proposals for the Medical Surgical Prime Vendor (Med/Surg PV) Program, which aims to provide medical and surgical supplies across three Global Regions: North, South, and West. This procurement involves awarding Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for both Primary and Backup vendors, facilitating the delivery of a wide range of commercially available medical supplies to various military and federal healthcare facilities. The program is crucial for ensuring that Medical Treatment Facilities (MTFs) and operational customers have timely access to essential medical products, thereby supporting military readiness and healthcare operations. Interested vendors must submit their proposals electronically via the DLA Internet Bid Board System (DIBBS) by January 8, 2026, at 3:00 PM Local Philadelphia Time, and can direct inquiries to Beatrice Lopez-Pollard at beatrice.lopez-pollard@dla.mil or Joshua Tankel at Joshua.Tankel@dla.mil.